Treatment of Autoimmune Patients with CD19-CAR T Cells Results in Long-Term Drug-Free Remission or No Progression
Fabian Müller from the University Clinic of Erlangen presented updated data on the treatment of autoimmune patients with CD19-CAR T-cell therapy at ASH 2024. Data from 35 patients demonstrated a 100% remission rate at six months with a strong safety profile and deep B-cell depletion. Long-term follow-ups revealed long-term drug-free remission or no progression, with disease recurrence in only one patient
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in